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Cost, Effectiveness, and Value
How to Judge?
Universal health coverage is a global aspiration sup-
ported by both the World Health Organization1 and the
UnitedNations.2 TheWorldHealthOrganizationhas de-
fineduniversalhealthcoverageasensuringthat“allpeople
obtain the health services they need without suffering
financial hardshipwhen paying for them.”1 TheUN reso-
lution supporting universal health coverage specifically
avoided defining a particular type of health financing
system, but called on member states “to ensure that
health financing systems evolve so as to avoid signifi-
cant direct payments at the point of delivery.”2
The resources available to financehealth care in in-
dividual countries are closely correlatedwith thewealth
of those countries.3 Richer countries spend more on
health care thanpoorer ones; and there is a remarkably
close correlation between a country’s gross domestic
product and its expenditure on health care, evenwhen
public and private resources for health care are
combined.3 No country, however, is sufficiently re-
sourced to be able tomeet all the aspirations of univer-
sal health coverage. Priorities have to be made in the
trade-off between the cost of an intervention (whether
diagnostic or therapeutic) and theadditional benefit as-
sociated with the intervention.
Therelationshipbetweencostandeffectivenesscan
be depicted3 as a cost-effectiveness plane (Figure). In-
terventions that are more expensive but less effective
(quadrantAintheFigure)willobviouslyberejected.Those
interventions that are less expensive but also less effec-
tive (quadrant B) would be more challenging for deci-
sionmakersbut in reality areunusual. Interventions that
aremoreeffectivebut lessexpensive(quadrantC)should
be readily adopted, but are relatively uncommon. The
moreexpensiveandmoreeffective interventions inquad-
rantDposerealproblemsfordecisionmakers inbothde-
velopedanddevelopingcountries.Howmuch in theway
ofadditional costs, in relation to theanticipated increase
in effectiveness, canahealth care systemaffordwithout
displacing othermore effective interventions?
In attempting to answer this question, this View-
point focusesonpharmaceutical agents, considering the
concerns involving thehighcostsof someof thesehighly
effectiveproducts.However, the sameprinciples apply
equally to devices, diagnostic techniques, and other
health care delivery systems.
Costs
The costs of an intervention are, in theory, easy to de-
fine. They include the acquisition costs of the interven-
tion, the costs of its administration, and the savings
(sometimes called cost offsets) that accrue fromuse of
an intervention. The true acquisition costs of newphar-
maceuticals are often opaquebecause of commercially
confidential discounts that payers in many developed
countriesnegotiateandareoftensubstantially less than
the listprice. Indevelopingcountries,payersshouldsimi-
larly negotiate for lowerprices for products fromdevel-
oped countries.
Effectiveness
The evidence of the effectiveness of an intervention
might seem easy to define. Regulatory authorities, for
example, rigorously assess the evidence of clinical ef-
fectiveness of new pharmaceutical agents before they
are marketed. But, again, there are difficulties.
First, evidence for the clinical effectiveness at the
timeanewproduct ismarketedwill generallyhavebeen
basedonplacebo-controlledstudies,activecomparator-
controlled studies, or a combination of the 2. Theprob-
lem is that this approach ignores the fact that there are
often substantial differences within and between dif-
ferent health care systems in their accepted standards
of care and hence the relevant comparators.4 Analytic
techniques such as indirect comparisons and network
analyses3 can help overcome these difficulties but re-
quire considerable expertise in application.
The secondproblem in the evaluation of clinical ef-
fectiveness is that methods of determining effective-
ness are often disease or condition specific. Organiza-
tions suchas theAmericanSociety of ClinicalOncology,
theEuropeanSociety forMedicalOncology, and theMe-
morial Sloan Kettering Cancer Center all use ap-
proaches that evaluate specific response rates or sur-
vival rates5 among treatedpatients. Even though these
techniques provide evidence of effectiveness in spe-
cific conditions, they are of virtually no use to organiza-
tions seeking tocompare thecostsandbenefitsof treat-
ingonecondition comparedwith another. For example,
howarepayers expected to compare thevalueof anew
treatment for breast cancer with a new treatment for
schizophrenia if thebenefits areexpressed in totallydif-
ferent ways?
An alternative approach seeks to assess effective-
ness in a manner that can be used to make appropriate
comparisons between different conditions. Groups
such as the American College of Cardiology, the Insti-
tute for Clinical Effectiveness Research in the United
States, and the National Institute for Health and Clinical
Effectiveness in the United Kingdom use metrics such
as the quality-adjusted life-years (QALYs) gained so the
clinical benefits of interventions can be compared
across disease states. In this way, payers can negotiate
acquisition prices as well as make informed decisions
about relative priorities. The use of QALYs is beneficial
for policy makers more generally as well as to develop-
ers of clinical guidelines.
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Values and Judgments
Decisions about whether to recommend or adopt particular inter-
ventions also require making value judgments, which generally in-
volve scientific and social perspectives.6
Scientific value judgments are concerned with (1) considering
how reliable the evidence base is; (2) whether the results are gen-
eralizable to the population likely to be treated; (3) whether sub-
groupanalysesareappropriate;and(4)whether thechanges inqual-
ity of life (an essential component of estimating the QALYs) have
been appropriately captured. Contrary to popular belief, these are
all judgments. No clinical trial is ever perfect in that all have limita-
tions anddeficiencies.Do these invalidate the results?Are the find-
ings generalizable to use in the real world?
In a misguided attempt to avoid making such scientific judg-
ments, some resort to applying hierarchies of evidence,7 many of
which have been published during the past 30 years. All hierar-
chies assign randomized clinical trials at the highest evidence lev-
els, with observational studies at lower levels. However, the order-
ing of evidence in this way is inappropriate because it is not the
methodsper se that are important butwhether themethods are fit
for purpose. As a result, confidence of the benefits of penicillin for
the treatmentofpneumonia7 (originallybasedonevidence fromob-
servational studies) is no less secure than confidence in the ben-
efits of trastuzumab in the early treatment of breast cancer based
on randomized clinical trials.
Decision makers or payers also have to make social value judg-
ments based on social considerations rather than biomedical
science.6 What threshold should be used to distinguish between
cost-effective and cost-ineffective interventions? Should added
weight be given to the severity of the underlying condition in
deciding whether an intervention should be provided by a health
care system? Even when an intervention appears to be cost-
effective with a cost of $50000 per QALY, the overall budgetary
effect may be substantial if large numbers of patients are likely to
seek that intervention. An important issue becomes what thresh-
old should be applied in considering the affordability of an inter-
vention for the health care system as a whole?
Moreover, how should the tensions between utilitarianism
(ie, the greatest good for the greatest number) be resolved against
egalitarianism (ie, treating everyone equally)? For example, how
should health inequalities based on socioeconomic and ethnic fac-
tors be incorporated into decisionmaking?
All of thesematters that have to be especially considered in de-
cision making by health care systems for which significant financial
contributions aremade frompublic funds. In some countries, politi-
ciansandgovernmentsmakethesedeterminations,whereas inother
countries, theresponsibility is largelyhandedovertoarms-lengthbod-
ies suchas theNational Institute forHealthandClinicalEffectiveness
in theUnitedKingdom. It isunclear toobserversof theUShealthcare
systemwho in the United States ismaking these decisions.
Conclusions
Theneed forpriority setting in theglobal search foruniversal health
coverage is clear.Howthis is undertaken is a regional or national en-
deavor that depends as much on the prevailing political and socio-
economic circumstances as it does the underlying biomedical sci-
ence.Butultimately, all health care systemsmust embraceboth the
opportunities and the challenges that are involved.
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